Updates from American Society of Clinical Oncology (ASCO) Solid Tumor Webinar
August 23, 2018
5:00 – 6:00 pm Central
Credits: 1 hour BCOP and/or 1 hour ACPE
BCOP credits are available to earn until February 19, 2019
Individual webinar pricing: $40 (member) / $70 (non-member)
This may also be purchased as part of the 2018 BCOP Webinar Bundle.
HOPA is pleased to present the third of a five-webinar series, which will review key findings from clinical and translational research, and data presented at national oncology meetings.
- Evaluate new interventions in supportive care for their potential to ameliorate therapy-related side effects and support patient adherence with and tolerance of therapy.
- Assess new information on the role of pharmacogenomics the pharmacokinetics, pharmacodynamics, or in the clinical management of oncology therapy related medications.
- Interpret research findings of key abstracts expected to impact clinical practice and treatment strategies in hematology/oncology.
- • Discuss advances and future directions in cancer immunotherapy in the treatment of solid tumors.
Dr. Cindy O’Bryant, PharmD BCOP FCCP FHOPA
Cindy L. O’Bryant is a Professor with the Department of Clinical Pharmacy at the University of Colorado Skaggs School Pharmacy and Pharmaceutical Sciences. Dr. O’Bryant serves as the director of the Oncology Pharmacy Residency Program and Co-Director of the Oncology Clinical Research Fellowship. Dr. O’Bryant has served as President of the Hematology/Oncology Pharmacy Association and Chair of the American College of Clinical Pharmacy Hem/Onc PRN. Her current practice is at the University of Colorado Cancer Center in the Developmental Therapeutics (Phase 1)/ GI/ Head and Neck cancer program where she is currently a principal investigator of Phase 1 clinical trials and organ dysfunction trials. Her areas of interest and research include oncology early drug development, organ dysfunction resulting anticancer agent dose modification, and supportive care/education issues in cancer treatment.
Disclosure:Astra Zenca – Principal Investigator, Research Grant to my institution, Amgen – Speaker – honoraria, Pharmacy Times Continuing Education – co-authored continuing education – honoraria, University Learning Systems – Speaker – honoraria
This activity is intended for intermediate/advanced hematology/oncology pharmacists. This activity has been approved for 1 contact hour (.1 CEUs) under the ACPE universal activity number 0465-0000-18-059-H04-P.
The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. An ACPE statement of credit will be issued only upon completion of the pre/post- assessment and a post-activity evaluation form. The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Board of Pharmacy Specialties (BPS) as a provider of board certification oncology credit (BCOP). A BCOP statement of credit will be issued only upon completion of a post-activity evaluation form and posttest, with a passing grade of 75% achieved. BCOP test must be completed by February 19, 2019.
The Hematology/Oncology Pharmacy Association (HOPA) is accredited by the Board of Pharmacy Specialties (BPS) as a provider of board certification oncology credit (BCOP). A BCOP statement of credit will be issued only upon completion of a post-activity evaluation form and posttest, with a passing grade of 75% achieved. Test must be completed by February 19, 2019.
Disclosure of Conflicts of Interest: The Hematology/Oncology Pharmacy Association (HOPA) assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CE activities. All relevant conflicts of interest that are identified are thoroughly vetted by HOPA for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. HOPA is committed to providing its learners with high-quality CE activities and related materials that promote improvements of quality in healthcare and not a specific proprietary business interest of a commercial interest.
Reported Areas of Conflict: Planners and Managers Hematology/Oncology Pharmacy Association does not view the existence of relationships as an implication of bias or that the value of the material is decreased. The content of the activity was planned to be balanced, objective, and scientifically rigorous. Occasionally, authors may express opinions that represent their own viewpoint. Conclusions drawn by participants should be derived from objective analysis of scientific data. Unlabeled/unapproved uses of drugs. All faculty have indicated that they have not referenced unlabeled/unapproved uses of drugs and devices.